GPR75-ASB3

Across TCGA pan-cancer cohorts, GPR75-ASB3 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of GPR75-ASB3’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where GPR75-ASB3 RNA is repressed in tumor relative to normal tissue. In most cancer types GPR75-ASB3 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

THCA, UCEC, and STAD are the cancer types where GPR75-ASB3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GPR75-ASB3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	All	−0.093	<.001	8	view →
UCEC	All	All	−0.049	.027	6	view →
STAD	All	II,III,IV	+0.094	.006	3	view →
CHOL	All	All	+0.068	.035	3	view →
BRCA	All	III,IV	−0.066	.014	2	view →
LIHC	All	All	+0.025	.007	2	view →
LUAD	All	III,IV	−0.057	.034	1	view →
BLCA	Female	IV	+0.026	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

GPR75-ASB3–THCA

Open the THCA breakdown →